Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Sep 19;20(5):4244–4252. doi: 10.3892/mmr.2019.10690

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © Zhou et al.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

PMC Copyright notice

Figure 2. — CTHRC1 protein expression levels are elevated in PRAD tumors, and this is associated with tumor recurrence and poor clinical outcome. Scale bar, 100 µm; original magnification, ×400. (A) DFS rates were compared between the CTHRC1^high and CTHRC1^low groups. Analysis of DFS was accomplished using The Cancer Genome Atlas cohort. (B) Increases in CTHRC1 protein expression in PRAD generated from the validation cohort, followed by immunohistochemistry straining for CTHRC1. Typical images of CTHRC1 staining in tumors without recurrence (n=80) or with recurrence (n=42). (C) CTHRC1 protein expression levels were markedly increased in prostate cancer LNCaP and PC-3 cell lines compared with human prostate normal cells RwPE-2. CTHRC1, collagen triple helix repeat containing 1; HR, hazard ratio; PRAD, prostate adenocarcinoma; DFS, disease free survival.